Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NNC 0113 2023

Drug Profile

NNC 0113 2023

Alternative Names: NN9023; NNC0113-2023; OG2023SC

Latest Information Update: 12 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics
  • Mechanism of Action Glucagon-like peptide 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 30 Sep 2019 Discontinued - Phase-I for Type 2 diabetes mellitus (In volunteers) in USA (PO) in the third quarter of 2019
  • 05 Dec 2018 Novo Nordisk completes a phase I trial in Type-2 diabetes mellitus (In volunteers) in USA (PO) (NCT03617081)
  • 09 Aug 2018 Phase-I clinical trials in Type-2 diabetes mellitus (In volunteers) in USA (PO) (NCT03617081)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top